This week, the regulator wrote the script. FDA opened the door on AI-monitored real-time clinical trials with named pharma collaborators. Science published peer-reviewed evidence of physician-level LLM reasoning. OpenEvidence, reportedly used by 40% of US physicians, pulled its product from the EU and UK over AI Act uncertainty. Pharma extended